Search research articles
Contact Us
Filters
Showing results (431-440 of 1,623) with videos related to
Page
of 163
Sort By:
Current Oncology Reports
|
September 10, 2008
Diagnostic evaluations of unproven clinical utility in oncology: a real-life example of their harmful consequences
Maurie Markman
Oncology
|
November 1, 2007
Increasing entry of the elderly into cancer clinical trials: difficult, but unquestionably necessary
Maurie Markman
Gynecologic Oncology
|
August 7, 2008
The remarkable "paclitaxel story": how many chapters remain to be written?
Maurie Markman
Current Oncology Reports
|
August 19, 2008
Risk of toxicity versus risk of death: a complex equation in the management of highly curable malignancies
Maurie Markman
Cancer Treatment and Research
|
July 18, 2007
Current status of intraperitoneal antineoplastic drug delivery
M Markman
Gynecologic Oncology
|
January 30, 2009
Hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer: A critical need for an evidence-based evaluation
Maurie Markman
Gynecologic Oncology
|
January 14, 2009
A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer
Maurie Markman
Journal of Cancer Research and Clinical Oncology
|
January 1, 1994
85th annual meeting of the American Association for Cancer Research. San Francisco, California, April 1994
M Markman
Journal of the American Dental Association (1939)
|
March 31, 2020
More on second opinions
Stanley Markman
Journal of the New Jersey Dental Association
|
August 22, 2014
Referred pain
Stanley Markman
Page
of 163
Search research articles
Search
Showing results (431-440 of 1,623) with videos related to
Sort By:
Page
of 163
Current Oncology Reports
|
September 10, 2008
Diagnostic evaluations of unproven clinical utility in oncology: a real-life example of their harmful consequences
Maurie Markman
Oncology
|
November 1, 2007
Increasing entry of the elderly into cancer clinical trials: difficult, but unquestionably necessary
Maurie Markman
Gynecologic Oncology
|
August 7, 2008
The remarkable "paclitaxel story": how many chapters remain to be written?
Maurie Markman
Current Oncology Reports
|
August 19, 2008
Risk of toxicity versus risk of death: a complex equation in the management of highly curable malignancies
Maurie Markman
Cancer Treatment and Research
|
July 18, 2007
Current status of intraperitoneal antineoplastic drug delivery
M Markman
Gynecologic Oncology
|
January 30, 2009
Hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer: A critical need for an evidence-based evaluation
Maurie Markman
Gynecologic Oncology
|
January 14, 2009
A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer
Maurie Markman
Journal of Cancer Research and Clinical Oncology
|
January 1, 1994
85th annual meeting of the American Association for Cancer Research. San Francisco, California, April 1994
M Markman
Journal of the American Dental Association (1939)
|
March 31, 2020
More on second opinions
Stanley Markman
Journal of the New Jersey Dental Association
|
August 22, 2014
Referred pain
Stanley Markman
Page
of 163